Premium
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Author(s) -
Amstutz Ursula,
Henricks Linda M.,
Offer Steven M.,
Barbarino Julia,
Schellens Jan H.M.,
Swen Jesse J.,
Klein Teri E.,
McLeod Howard L.,
Caudle Kelly E.,
Diasio Robert B.,
Schwab Matthias
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.911
Subject(s) - dpyd , capecitabine , dosing , guideline , dihydropyrimidine dehydrogenase , pharmacogenetics , medicine , fluorouracil , genotype , oncology , pharmacology , cancer , thymidylate synthase , biology , genetics , pathology , colorectal cancer , gene
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).